Current role of short-term intensive insulin strategies in newly diagnosed type 2 diabetes

Journal of Diabetes

Volumn 5, Issue 3, 2013, Pages 268-274

  Xu, Wen ^a   Weng, Jianping ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

cell function; Glycemic remission; Insulin therapy; Type 2 diabetes

Indexed keywords

GLICLAZIDE; GLUCOSE; INSULIN; METFORMIN;

CELL FUNCTION; DRUG EFFICACY; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REMISSION; REVIEW;

GLYCEMIC REMISSION; INSULIN THERAPY; TYPE 2 DIABETES; Β-CELL FUNCTION;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84881553151     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12054     Document Type: Review

References (55)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010; 87: 4-14.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published erratum appears in Lancet 1999;354:602]. Lancet. 1998; 352: 837-853.
3. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) [published erratum appears in Lancet 1998;352:1558]. Lancet. 1998; 352: 854-865.
4. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359: 1577-1589.
5. Ilkova H, Glaser B, Tunckale A, Bagriacik N, Cerasi E. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care. 1997; 20: 1353-1356.
6. Li Y, Xu W, Liao Z etal. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care. 2004; 27: 2597-2602.
7. Weng J, Li Y, Xu W etal. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: A multicentre randomised parallel-group trial. Lancet. 2008; 371: 1753-1760.
8. Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care. 2004; 27: 1028-1032.
9. Hu Y, Li L, Xu Y etal. Short-term intensive therapy in newly diagnosed type 2 diabetes partially restores both insulin sensitivity and beta-cell function in subjects with long-term remission. Diabetes Care. 2011; 34: 1848-1853.
10. Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Invest. 2006; 116: 1802-1812.
11. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009; 58: 773-795.
12. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia. 2003; 46: 3-19.
13. Rahier J, Guiot Y, Goebbels RM, Sempoux C, Henquin JC. Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab. 2008; 10 (Suppl. 4): 32-42.
14. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003; 52: 102-110.
15. UK Prospective Diabetes Study Group. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: A progressive disease [published erratum appears in Diabetes 1996; 45(11): 1655]. Diabetes. 1995; 44: 1249-1258.
16. Yki-Jarvinen H. Glucose toxicity. Endocr Rev. 1992; 13: 415-431.
17. Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev. 2007; 28: 187-218.
18. Gerich JE. Is reduced first-phase insulin release the earliest detectable abnormality in individuals destined to develop type 2 diabetes? Diabetes. 2002; 51 (Suppl. 1): S117-121.
19. Leahy JL, Bonner-Weir S, Weir GC. Beta-cell dysfunction induced by chronic hyperglycemia. Current ideas on mechanism of impaired glucose-induced insulin secretion. Diabetes Care. 1992; 15: 442-455.
20. Gleason CE, Gonzalez M, Harmon JS, Robertson RP. Determinants of glucose toxicity and its reversibility in the pancreatic islet beta-cell line, HIT-T15. Am J Physiol Endocrinol Metab. 2000; 279: E997-1002.
21. Retnakaran R, Yakubovich N, Qi Y, Opsteen C, Zinman B. The response to short-term intensive insulin therapy in type 2 diabetes. Diabetes Obes Metab. 2010; 12: 65-71.
22. Li HQ, Wang BP, Deng XL etal. Insulin improves beta-cell function in glucose-intolerant rat models induced by feeding a high-fat diet. Metabolism. 2011; 60: 1566-1574.
23. Hugl SR, White MF, Rhodes CJ. Insulin-like growth factor I (IGF-I)-stimulated pancreatic beta-cell growth is glucose-dependent. Synergistic activation of insulin receptor substrate-mediated signal transduction pathways by glucose and IGF-I in INS-1 cells. J Biol Chem. 1998; 273: 17771-17779.
24. Donath MY, Storling J, Maedler K, Mandrup-Poulsen T. Inflammatory mediators and islet beta-cell failure: A link between type 1 and type 2 diabetes. J Mol Med. 2003; 81: 455-470.
25. Alvarsson M, Sundkvist G, Lager I etal. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care. 2003; 26: 2231-2237.
26. Chen HS, Wu TE, Jap TS, Hsiao LC, Lee SH, Lin HD. Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care. 2008; 31: 1927-1932.
27. Li YB, Zeng LY, Shi LX etal. [The effects of early intensive therapy on islet beta cell function and long-term glycemia control in newly diagnosed type 2 diabetic patients with different fasting plasma glucose levels.]. Zhonghua Nei Ke Za Zhi. 2010; 49: 9-13. (in Chinese).
28. Xu W, Li YB, Deng WP, Hao YT, Weng JP. Remission of hyperglycemia following intensive insulin therapy in newly diagnosed type 2 diabetic patients: A long-term follow-up study. Chin Med J. 2009; 122: 2554-2559.
29. McFarlane SI, Chaiken RL, Hirsch S, Harrington P, Lebovitz HE, Banerji MA. Near-normoglycaemic remission in African-Americans with Type 2 diabetes mellitus is associated with recovery of beta cell function. Diabet Med. 2001; 18: 10-16.
30. Pratipanawatr T, Cusi K, Ngo P, Pratipanawatr W, Mandarino LJ, DeFronzo RA. Normalization of plasma glucose concentration by insulin therapy improves insulin-stimulated glycogen synthesis in type 2 diabetes. Diabetes. 2002; 51: 462-468.
31. Chen X, Yu QQ, Zhu YH etal. Insulin therapy stimulates lipid synthesis and improves endocrine functions of adipocytes in dietary obese C57BL/6 mice. Acta Pharmacol Sin. 2010; 31: 341-346.
32. Li F, Zhao T, Wen X. Changes in serum adiponectin concentrations and endothelial function after intensive insulin treatment in people with newly diagnosed type 2 diabetes: A pilot study. Diabetes Res Clin Pract. 2011; 94: 186-192.
33. Sun W, Bi Y, Liang H etal. Inhibition of obesity-induced hepatic ER stress by early insulin therapy in obese diabetic rats. Endocrine. 2011; 39: 235-241.
34. Sun WP, Bi Y, Liang H etal. [Effects of early insulin therapy on sterol regulatory element binding protein 1 pathway and lipid accumulation in liver of type 2 diabetic rats.]. Zhonghua Yi Xue Za Zhi. 2011; 91: 1809-1812. (in Chinese).
35. Rakatzi I, Seipke G, Eckel J. [LysB3, GluB29] insulin: A novel insulin analog with enhanced beta-cell protective action. Biochem Biophys Res Commun. 2003; 310: 852-859.
36. van Haeften TW, Twickler TB. Insulin-like growth factors and pancreas beta cells. Eur J Clin Invest. 2004; 34: 249-255.
37. Bloomgarden ZT. Exploring treatment strategies for type 2 diabetes. Diabetes Care. 2007; 30: 2737-2745.
38. LeRoith D, Fonseca V, Vinik A. Metabolic memory in diabetes: Focus on insulin. Diabetes Metab Res Rev. 2005; 21: 85-90.
39. Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: The 10-year follow-up of the Belfast Diet Study. Diabet Med. 1998; 15: 290-296.
40. DeVries JH, Siegelaar S, Holleman F, Hoekstra JB. Intensive insulin therapy in patients with type 2 diabetes. Lancet. 2008; 372: 717.
41. Hemmingsen B, Lund SS, Gluud C etal. Intensive glycaemic control for patients with type 2 diabetes: Systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ. 2011; 343: d6898.
42. Kahn SE. Clinical review 135: The importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab. 2011; 86: 4047-4058.
43. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004; 27: 1535-1540.
44. Peyrot M, Rubin RR, Lauritzen T etal. Resistance to insulin therapy among patients and providers: Results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005; 28: 2673-2679.
45. Korytkowski M. When oral agents fail: Practical barriers to starting insulin. Int J Obes Relat Metab Disord. 2002; 26 (Suppl. 3): S18-24.
46. Opsteen C, Qi Y, Zinman B, Retnakaran R. Effect of short-term intensive insulin therapy on quality of life in type 2 diabetes. J Eval Clin Pract. 2012; 18: 256-261.
47. Noh YH, Lee SM, Kim EJ etal. Improvement of cardiovascular risk factors in patients with type 2 diabetes after long-term continuous subcutaneous insulin infusion. Diabetes Metab Res Rev. 2008; 24: 384-391.
48. Park S, Choi SB. Induction of long-term normoglycemia without medication in Korean type 2 diabetes patients after continuous subcutaneous insulin infusion therapy. Diabetes Metab Res Rev. 2003; 19: 124-130.
49. Lingvay I, Legendre JL, Kaloyanova PF, Zhang S, Adams-Huet B. Raskin P 2009. Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: Which is better? Diabetes Care. 2009; 32: 1789-1795.
50. Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G. Triple therapy in type 2 diabetes: Insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care. 2006; 29: 554-559.
51. Unger RH, Scherer PE. Gluttony, sloth and the metabolic syndrome: A roadmap to lipotoxicity. Trends Endocrinol Metab. 2010; 21: 345-352.
52. Nolan CJ, Prentki M. The islet beta-cell: Fuel responsive and vulnerable. Trends Endocrinol Metab. 2008; 19: 285-291.
53. Gerstein HC, Bosch J, Dagenais GR etal. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012; 367: 319-328.
54. Li R, Zhang P, Barker LE, Chowdhury FM, Zhang X. Cost-effectiveness of interventions to prevent and control diabetes mellitus: A systematic review. Diabetes Care. 2010; 33: 1872-1894.
55. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008; 358: 580-591.